Antibody Drug Conjugates And The Global Research Landscape

In recent years, antibody-drug conjugates (ADCs) have emerged as a highly promising category of targeted cancer therapies. These innovative compounds consist of monoclonal antibodies chemically linked to cytotoxic drugs, offering a selective approach to targeting cancer cells while minimizing systemic exposure in patients. Globally, there are currently around 12 ADCs approved for treating both solid and hematological tumors, with three of them achieving blockbuster status.

Learn more about how ADCs represent a significant advancement in cancer treatment and could potentially revolutionize the field by reducing the often severe side effects associated with traditional chemotherapy.